Skip to main content

MoneyWorks4Me

Shilpa Medicare informs about disclosure

26 Aug 2024 Evaluate
Shilpa Medicare has informed that the company has successfully completed phase 3 clinical studies of its novel product SMLNUD07 - Nor Ursodeoxycholic Acid (NorUDCA) tablets that is expected to revolutionise the treatment of patients suffering from Nonalcoholic Fatty Liver Disease (NAFLD).

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1860.00
Dr. Reddys Labs. 1371.20
Cipla 1409.00
Lupin 1990.00
Zydus Lifesciences 1195.00
View more..